"Decipher prostate test receives high evidence rating in NCCN guidelines"

Decipher prostate test receives high evidence rating in NCCN guidelines (2024) Urology Times article

"The Decipher Prostate Genomic Classifier has received a Level 1B evidence rating, the highest rating among molecular tests, in the 2024 National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, according to a news release by Veracyte, the developer of the test.
..."

Veracyte's press release cited in the above article:

Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines (2024)

Djin

Post Edited (DjinTonic) : 3/1/2024 8:13:15 AM (GMT-8)

Mumbo said...
Looks like the marketing department wrote this…

The press release? It clearly has one foot in marketing--that's one meaning of "press."

The other article points to Decipher results influencing SOC:

"In patients with NCCN high-risk and a Decipher score of 0.45 of lower or 0.60 or higher, the guidelines compare radiotherapy plus long-term ADT (LT-ADT) and ST-ADT. Based on data from a meta-analysis of 3 phase 3 trials (NRG/RTOG 9202, 9413, and 9902), the guidelines recommend that radiotherapy plus LT-ADT be the option for most patients with NCCN high-risk disease, regardless of the Decipher score. However, the guidelines note that patients with Decipher low-risk should be counseled that a shorter duration of ADT may be reasonable given that the benefit of LT-ADT over ST-ADT is smaller for patients with a low-risk Decipher score (3%) compared with high-risk (11%) when accounting for age, comorbidities, and patient preference.5"

Djin